natgillin/translations-raw huggingface dataset:
I den pædiatriske population (10-17 år) med bipolær lidelse, som fik behandling i op til 30 uger, var incidensen af lav serum-prolaktin hos piger (< 3 ng/ml) og drenge (< 2 ng/ml) henholdsvis 28,0 % og 53,3 %.
In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (< 3 ng/ml) and males (< 2 ng/ml) was 28.0% and 53.3%, respectively.
I den pædiatriske population (10-17 år) med bipolær lidelse, som fik behandling i op til 30 uger, var incidensen af lav serum-prolaktin hos piger (< 3 ng/ml) og drenge (< 2 ng/ml) henholdsvis 28,0 % og 53,3 %.
In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (<3 ng/ml) and males (<2 ng/ml) was 28.0% and 53.3%, respectively.
I den randomiserede aktive kontrollerede undersøgelse var 6 måneders PFS signifikant større for TMZ end for procarbazin (henholdsvis 21 % versus 8 % - chi-square p = 0,008) med median PFS på henholdsvis 2,89 og 1,88 måneder (log rank p = 0,0063).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
I den randomiserede aktive kontrollerede undersøgelse var 6 måneders PFS signifikant større for TMZ end for procarbazin (henholdsvis 21 % versus 8 % - chi-square p = 0,008) med median PFS på henholdsvis 2,89 og 1,88 måneder (log rank p = 0,0063).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than forprocarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
I den randomiserede aktive kontrollerede undersøgelse var 6 måneders PFS signifikant større for TMZ end for procarbazin (henholdsvis 21 % versus 8 % - chi-square p = 0,008) med median PFS på henholdsvis 2,89 og 1,88 måneder (log rank p = 0,33).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % vs 8 %, respectively – chi-square p = 0.008) with median PFS of 2.89 and
I den randomiserede aktive kontrollerede undersøgelse var 6 måneders PFS signifikant større for TMZ end for procarbazin (henholdsvis 21 % versus 8 % - chi-square p=0,008) med median PFS på henholdsvis 2,89 og 1,88 måneder (log rank p = 0,33).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % vs 8 %, respectively – chi-square p=0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p=0.0063).
I den randomiserede aktivt kontrollerede undersøgelse var PFS efter 6 måneder signifikant længere for TMZ end for procarbazin (hhv.
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21% vs.
I den randomiserede periode af de pivotale studier var andelen af patienter, som oplevede trombocytopeni, lavere for PV-patienter (24,5%) sammenlignet med MF-patienter (69,8%).
In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (24.5%) patients compared to MF (69.8%) patients.
I den randomiserede periode af de pivotale studier var anæmi mindre hyppig hos PV-patienter end hos MF-patienter (43,6% versus 82,4%).
In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (43.6% versus 82.4%).
I den randomiserede periode af det pivotale studie for PV blev neutropeni rapporteret hos to patienter (1,8%), hvor en af patienterne udviklede CTCAE grad 4 neutropeni.
In the randomised period of the pivotal study in PV patients, neutropenia was reported in two patients (1.8%) of which one patient developed CTCAE grade 4 neutropenia.
I den randomiserede periode af det pivotale studie hos PV-patienter blev der rapporteret en (0,9%) CTCAE grad 3 og ingen grad 4 urinvejsinfektion.
In the randomised period of the pivotal study in PV patients, one (0.9%) CTCAE grade 3 and no grade 4 urinary tract infection was reported.
I den randomiserede periode af det pivotale studie med PV-patienter blev blødningshændelser (inklusive intrakranielle og gastrointestinale blødninger, blå mærker og andre blødningshændelser) rapporteret hos 20% af patienterne i Jakavi-armen og hos 15,3% af patienterne i armen med den bedste tilgængelige terapi.
In the randomised period of the pivotal study in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 20% of patients treated with Jakavi and 15.3% patients receiving best available therapy.
I den samlede analyse af 100 PAH-patienter fra de ikke-kontrollerede pædiatriske studier FUTURE 1/2 og FUTURE 3/forlængelse blev der set stigning i leveraminotransferaser til ≥ 3  ULN hos 2% af patienterne.
In the pooled analysis of 100 PAH patients from uncontrolled paediatric studies FUTURE 1/2 and FUTURE 3/Extension, elevations in liver aminotransferases ≥ 3  ULN were observed in 2% of patients.
I den samlede analyse af 100 PAH-patienter fra de ikke-kontrollerede pædiatriske studier FUTURE 1/2 og FUTURE 3/forlængelse blev der set stigning ileveraminotransferaser til ≥ 3  ULN hos 2% af patienterne.
In the pooled analysis of 100 PAH patients from uncontrolled paediatric studies FUTURE 1/2 and FUTURE 3/Extension, elevations in liver aminotransferases ≥ 3  ULN were observed in 2% of patients.
I den samlede analyse af behandlingserfarne patienter var hyppigheden for seponering af behandling på grund af bivirkninger 3,9% hos patienter, der fik ISENTRESS + OBT, og 4,6% hos patienter, der fik placebo + OBT.
In the pooled analysis of treatment-experienced patients, the rates of discontinuation of therapy due to adverse reactions were 3.9 % in patients receiving ISENTRESS + OBT and 4.6 % in patients receiving placebo + OBT.
I den samlede analyse af fase 3-studier, havde 16 % af patienterne baseline- NS5A-RAVs identificeret ved populationssekventering eller dyb sekventering uanset undertype.
In the pooled analysis of the Phase 3 studies, 16% of patients had baseline NS5A RAVs identified by population or deep sequencing irrespective of subtype.
I den samlede analyse af fase III-studierne havde 380/1.023 (37 %) af patienterne virus med NS5A–RAV’er ved baseline.
In the pooled analysis of the Phase 3 studies, 380/1,023 (37%) patients’ virus had baseline NS5A RAVs.
I den samlede analyse af Kodiac 4 og Kodiac 5 (90, 88 og 99 patienter i hhv. placebo-, 12,5 mg- og 25 mg- grupperne) blev der set højere responsrater i denne population med 25 mg-dosen i forhold til placebo (p=0,040).
In a pooled analysis of Kodiac 4 and Kodiac 5 (90, 88 and 99 patients in the placebo, 12.5 mg and 25 mg groups respectively), higher response rates in this population was observed for the 25 mg dose group compared with placebo (p=0.040).
I den samlede analyse for C209 og C215 med patienter, der fik et baggrundsprogram med emtricitabin/tenofovir disoproxilfumarat, blev demografiske og baselinekarakteristika balanceret mellem rilpivirin- og efavirenz-armen.
In the pooled analysis for C209 and C215 of patients who received a background regimen of emtricitabine/tenofovir disoproxil fumarate, demographic and baseline characteristics were balanced between the rilpivirine and efavirenz arm.
I den samlede analyse for TMC278-C209 og TMC278-C215 af 1096 patienter, som fik et baggrundsregime (BR) med FTC/TDF, var demografiske karakteristika og karakteristika ved baseline afbalanceret mellem grupperne med rilpivirin og efavirenz (EFV).
In the pooled analysis for TMC278-C209 and TMC278-C215 of 1096 patients who received a background regimen (BR) of FTC/TDF, demographic and baseline characteristics were balanced between the rilpivirine and efavirenz (EFV) arms.
I den samlede analyse i uge 96 af patienter, der fik emtricitabin/tenofovirdisoproxilfumarat (FTC/TDF) + rilpivirinhydrochlorid i de kliniske fase 3-studier TMC278-C209 og TMC278-C215, havde hiv 1-isolater fra 43 patienter en aminosyresubstitution associeret med NNRTI- (n = 39) eller NRTI- (n = 41) resistens.
In the Week 96 pooled analysis for patients receiving emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) + rilpivirine hydrochloride in the Phase 3 clinical studies TMC278-C209 and TMC278-C215, HIV-1 isolates from 43 patients had an amino acid substitution associated with NNRTI (n = 39) or NRTI (n = 41) resistance.
I den samlede analyse var forholdet mellem hyppigheden (rate ratio) af forværringer til og med uge 24 hos personer i behandling med lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg hver 12. time, n=369) 0,61 (P<0,0001), hvilket udgør en reduktion på 39 % i forhold til placebo.
In the pooled analysis, the rate ratio of exacerbations through week 24 in subjects treated with lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg q12h; n=369) was 0.61 (P<0.0001), representing a reduction of 39% relative to placebo.
I den samlede effektanalyse af de to kliniske fase III-studier (C209 [ECHO] og C215 [THRIVE]) til og med uge 96 havde patienter i behandling med emtricitabin/tenofovirdisoproxilfumarat + rilpivirin med en viral belastning ved baseline på > 100.000 hiv 1-rna-kopier/ml en større risiko for virologisk svigt (17,6% med rilpivirin versus 7,6% med efavirenz) sammenlignet med patienter med en viral belastning ved baseline på ≤ 100.000 hiv 1-rna-kopier/ml (5,9% med rilpivirin versus 2,4% med efavirenz).
In the pooled efficacy analysis from the two Phase III clinical studies (C209 [ECHO] and C215 [THRIVE]) through 96 weeks, patients treated with emtricitabine/tenofovir disoproxil fumarate + rilpivirine with a baseline viral load > 100,000 HIV-1 RNA copies/mL had a greater risk of virologic failure (17.6% with rilpivirine versus 7.6% with efavirenz) compared to patients with a baseline viral load ≤ 100,000 HIV-1 RNA copies/mL (5.9% with rilpivirine versus 2.4% with efavirenz).
I den samlede ITT population var den kumilative resistenshyppighed for HBeAg-positive og HbeAg- negative patienter respektivt 40,8 % (131/321) og 18,9 % (37/196) efter 4 år.
In the overall ITT population the cumulative resistance rates at year 4 for HBeAg-positive and HBeAg-negative patients, was 40.8% (131/321) and 18.9% (37/196), respectively.
I den samlede population (n=31) resulterede 2 mg/kg to gange dagligt i en daglig eksponering på 8.535 ng·t/ml; AUC var 4.268 ng·t/ml (CV 61%).
In the overall population (n = 31), 2 mg/kg twice daily resulted in a daily exposure of 8,535 ng·h/mL; AUC was 4,268 ng·h/mL (CV: 61%).
I den samlede population af mænd og kvinder øgede en fordobling af dosis fra 50 mg til 100 mg mirabegron Cmax og AUCtau med en faktor på henholdsvis ca.
In the overall population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9- and
I den samlede population havde 86 % (227/263) dokumenteret respons på tidspunktet for første scanning (6 uger); 96 % (253/263) havde dokumentation for respons på tidspunktet for anden scanning (12 uger).
In the overall population, 86% (227/263) had documentation of response at the time of the first scan (6 weeks); 96% (253/263) had documentation of response at the time of the second scan (12 weeks).
I den samlede population var der en reduktion i forekomsten af laboratoriebekræftet klinisk influenza i husstande fra 20 % (27/136) i gruppen, der ikke fik forebyggelsesbehandling til 7 % (10/135) i den gruppe, som fik forebyggelsesbehandling (62,7 % reduktion [95 % konfidensinterval 26,0-81,2, p=0,0042]).
In the total population, there was a reduction in the incidence of laboratory-confirmed clinical influenza in households from 20 % (27 / 136) in the group not receiving prevention to 7 % (10 / 135) in the group receiving prevention (62.7 % reduction [95 % CI 26.0 – 81.2; p = 0.0042]).
I den samlede population var der en reduktion i forekomsten af laboratoriebekræftet klinisk influenza i husstande fra 20 % (27/136) i gruppen, der ikke fik forebyggelsesbehandling til 7 % (10/135) i den gruppe, som fik forebyggelsesbehandling (62,7 % reduktion [95 % konfidensinterval 26,0-81,2, p=0,0042]).
In the total population, there was a reduction in the incidence of laboratory-confirmed clinical influenza in households from 20 % (27/136) in the group not receiving prevention to 7 % (10/135) in the group receiving prevention (62.7 % reduction [95 % CI 26.0 – 81.2; p = 0.0042]).
I den samlede population var procentdelen af patienter, som opnåede et ACR-respons ved uge 52, generelt højere i Simponi 50 mg + MTX-gruppen sammenlignet med MTX alene, men forskellen var ikke signifikant (se Tabel 2).
At week 52 in the overall population, the percentage of patients in the Simponi 50 mg + MTX group who achieved an ACR response was generally higher but not significantly different when compared with MTX alone (see Table 2).
I den samlede population, uanset KRAS-status, var resultaterne rapporteret for cetuximab plus irinotecan (648 patienter) vs. irinotecan alene (650 patienter): median samlet overlevelsestid (OS) 10,71 vs.
In the overall population, irrespective of KRAS status, the results reported for cetuximab plus irinotecan (648 patients) vs. irinotecan alone (650 patients) were: median overall survival time (OS) 10.71 vs.
I den samlede pulje af guanfacinbehandlede patienter opstod døsighed hos 40,6 % og sedation hos 10,2 % af de guanfacinbehandlede patienter.
In the overall pool of guanfacine-treated patients, somnolence occurred in 40.6% and sedation in 10.2% of guanfacine-treated patients.
I den samlede randomiseringspopulation blev capecitabin vist at være bedre end 5- FU/LV mht. sygdomsfri overlevelse (hazard ratio 0,849; 95 % konfidensinterval 0,739 - 0,976; p = 0,0212) og mht. samlet overlevelse (hazard ratio 0,828; 95 % konfidensinterval 0,705 - 0,971; p =
In the all- randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
I den samlede randomiseringspopulation blev capecitabin vist at være bedre end 5-FU/LV mht. sygdomsfri overlevelse (hazard ratio 0,849; 95 % konfidensinterval 0,739 - 0,976; p = 0,0212) og mht. samlet overlevelse (hazard ratio 0,828; 95 % konfidensinterval 0,705 - 0,971; p = 0,0203).
In the all-randomised population, capecitabine was shown to be superior to 5-FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
I den samlede randomiseringspopulation blev capecitabin vist at være bedre end 5-FU/LV mht. sygdomsfri overlevelse (hazard ratio 0,849; 95% konfidensinterval 0,739 - 0,976; p=0,0212) og mht. samlet overlevelse (hazard ratio 0,828; 95% konfidensinterval 0,705 - 0,971; p=0,0203).
In the all- randomised population, capecitabine was shown to be superior to 5-FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739-0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705-0.971; p = 0.0203).
I den samlede resistensanalyse af de kliniske fase III-studier C209 og C215 ved uge 96 af patienter, der fik emtricitabin/tenofovirdisoproxilfumarat + rilpivirinhydrochlorid, var der 78 patienter med virologisk svigt, hvor information om genotype-resistens var tilgængelig for 71.
In the week 96 pooled resistance analysis for patients receiving emtricitabine/tenofovir disoproxil fumarate + rilpivirine hydrochloride in the Phase III clinical studies C209 and C215, there were 78 virologic failure patients with genotypic resistance information available for 71 of those patients.
I den sammenlagte sikkerhedspopulation fra CHAMPION-studierne var forekomsten af letal blødning inden for 30 dage efter dosering lav og svarende til forekomsten hos patienter, som fik cangrelor sammenlignet med clopidogrel (8 [0,1 %] vs.
In the pooled safety population from the CHAMPION trials, the incidence of fatal bleeding within 30 days of dosing was low and similar in patients who received cangrelor compared to clopidogrel (8 [0.1%] vs.
I den sammenlignende arm blev personer, der fik indledende heparinbehandling samtidigt med warfarin, titreret til et mål for INR på 2,0 til 3,0 efterfulgt af warfarin alene.
In the comparator arm, subjects received initial heparin therapy concurrently with warfarin, titrated to a target INR of 2.0 to 3.0, followed by warfarin alone.
I den sidste undersøgelse af patienter, som aldrig var blevet behandlet med DMARD'er, opnåede næsten 29 % af patienterne (189 ud af 655), der blev behandlet med Cimzia kombineret med methotrexat vedholdende lindring efter 52 ugers behandling sammenlignet med 15 % (32 ud af 213) af de patienter, der fik placebo i kombination med methotrexat.
In the last study in patients who had never received treatment with DMARDs, almost 29% of patients (189 out of 655) treated with Cimzia in combination with methotrexate were in sustained remission after 52 weeks of treatment, compared with 15% (32 out of 213) of patients receiving placebo with methotrexate.
I den sidstnævnte gruppe var mængden og påvisningsfrekvensen af kvantificerbare plasmakoncentrationer af 9-cis-retinsyre hos patienter med KS efter applikation af lægemidlet sammenlignelige med mængden og påvisningsfrekvensen af kvantificerbare plasmakoncentrationer af naturligt forekommende 9-cis-retinsyre i blodbanen hos ubehandlede personer.
In this latter group, the range and frequency of detection of quantifiable 9-cis-retinoic acid plasma concentrations in patients with KS after application of the medicinal product were comparable to the range and frequency of detection of quantifiable plasma concentrations of circulating, naturally-occurring 9-cis- retinoic acid in untreated individuals.
I den sjette undersøgelse (PALLAS) blev Multaq sammenlignet med placebo hos patienter på over 65 år med permanent atrieflimren og flere forskellige risikofaktorer.
A sixth study (PALLAS) compared Multaq with placebo in patients over 65 years of age with permanent atrial fibrillation and several risk factors.
I den store hovedundersøgelse af CML i kronisk fase virkede behandlingen hos 90 % af patienterne, så blodets indhold af blodplader og hvide blodlegemer igen vendte tilbage til de på forhånd definerede normalværdier.
In the larger main study of patients with chronic phase CML, 90% of the patients responded to treatment, with blood levels of platelets and white blood cells returning to within predefined, normal values.
I den store publicerede undersøgelse døde 46 % af de børn, der fik placebo (431 ud af 932), eller de havde neurologiske lidelser, sammenlignet med 40 % af de spædbørn, som fik koffeincitrat (377 ud af 937).
In the large published study, 46% of babies given placebo (431 out of 932) died or had neurological disabilities compared with 40% of babies given caffeine citrate (377 out of 937).
I den store undersøgelse hos patienter med koronar hjertesygdom uden klinisk hjerteinsufficiens sås der hos en specifik undergruppe af patienter med symptomatisk angina en lille, men signifikant, stigning i den kombinerede risiko for kardiovaskulært dødsfald eller ikkedødeligt hjertetilfælde ved Corlentor sammenlignet med placebo (3,4 % mod 2,9 % årlige incidensrater).
In the large study in patients with coronary heart disease and without clinical heart failure, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Corlentor compared with placebo (3.4% vs 2.9% yearly incidence rates).
I den store undersøgelse hos patienter med koronar hjertesygdom uden klinisk hjerteinsufficiens sås der hos en undergruppe af patienter med symptomatisk angina en lille, men signifikant, stigning i den kombinerede risiko for kardiovaskulært dødsfald eller ikkedødeligt hjertetilfælde ved Procoralan sammenlignet med placebo (3,4 % mod 2,9 % årlige incidensrater).
In the large study in patients with coronary heart disease and without clinical heart failure, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Procoralan compared with placebo (3.4% vs 2.9% yearly incidence rates).
I den store undersøgelse, hvis hovedfokus var lungebetændelse, lå andelen af børn med bakteriel lungebetændelse på 2,3 % (240 ud af over 10 000) blandt de børn, der fik Synflorix, sammenlignet med 3 % (304 ud af over 10 000) blandt de børn, der fik sammenligningsvaccinen.
In the large study that focused mainly on pneumonia, the percentage of children who had bacterial pneumonia was 2.3% (240 out of over 10,000) among those given Synflorix compared with 3% (304 out of over 10,000) among those given the comparator.
I den største af undersøgelserne opnåede 67 % af patienterne med essentiel trombocytæmi (628 ud af 934) og 66 % af dem, der ikke tålte eller ikke havde effekt af andre behandlinger (480 ud af 725), en komplet respons på Xagrid.
In the largest study, 67% of the patients with essential thrombocythaemia (628 out of 934), and 66% of those who could not tolerate or did not respond to other treatments (480 out of 725) had a complete response to Xagrid.
I den største undersøgelse, som omfattede 61 hæmofilipatienter med inhibitorer, blev 84 % af de 57 svære blødninger og 59 % af de 38 kirurgiske blødninger effektivt kontrolleret med NovoSeven.
In the largest study, which included 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
I den supplerende undersøgelse af Cimzia, der blev givet alene, opnåede flere patienter, der fik Cimzia, en reduktion på 20 % sammenlignet med dem, der fik placebo.
In the additional study of Cimzia used on its own, more patients who received Cimzia achieved 20% reductions compared with those who received placebo.
I den supplerende undersøgelse rapporterede patienterne, at de var "tilfredse" eller "meget tilfredse" med PecFent-behandlingen for cirka 90 % af tilfældene af gennembrudssmerter.
In the additional study, patients reported that they were ‘satisfied’ or ‘very satisfied’ with PecFent treatment for around 90% of breakthrough pain episodes.
I den terapeutiske og den supraterapeutiske arm havde henholdsvis 11 % og 18 % af forsøgspersonerne en QTcS mellem 450 og 480 ms.
In the therapeutic and the supra-therapeutic arm 11% and 18% of subjects, respectively, had a QTcS between 450 and 480 msec.
I den totale AKS-population viste en analyse af hvert af de sekundære endepunkter en signifikant fordel (p < 0.001) ved prasugrel sammenlignet med clopidogrel.
In the All ACS population, analysis of each of the secondary endpoints showed a significant benefit (p
I den tredje uge af behandlingen kan dosen
During the third week,
I den tredje uge anvender han eller hun Leganto 6 mg/24 timer og i den fjerde uge Leganto 8 mg/24 timer.
During the third week, he or she takes Leganto 6 mg/24 h and during the fourth week Leganto 8 mg/24 h.
I den tredje uge anvender han eller hun Neupro 6 mg/24 timer og i den fjerde uge Neupro 8 mg/24 timer.
During the third week, he or she takes Neupro 6 mg/24 h and during the fourth week Neupro 8 mg/24 h.
I den tredje uge anvendes Leganto 6 mg (æske mærket ”Uge 3”).
At the beginning of the third week, you should take Leganto 6 mg (package marked with “Week 3“).
I den tredje uge anvendes Neupro 6 mg (æske mærket ”Uge 3”).
At the beginning of the third week, you should take Neupro 6 mg (package marked with “Week 3“).
I den tredje undersøgelse blev alle 345 voksne patienter behandlet med ciclosporin, steroider og azathioprin ("trestofsbehandling").
In the third study, all 345 adults were taking ciclosporin, steroids and azathioprine (‘triple therapy’).
I den tredje undersøgelse blev Forxiga sammenlignet med et sulfonylurinstof (gli- pizid), idet begge stoffer blev anvendt i kombination med metformin hos 814 patienter.
A third study compared Forxiga with a sulphonylurea (glipizide), both taken in combination with metformin in 814 patients.